Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 159
Filter
2.
Int J Obstet Anesth ; 35: 26-32, 2018 08.
Article in English | MEDLINE | ID: mdl-29914782

ABSTRACT

BACKGROUND: Injection of local anesthetic into the transversus abdominis plane (TAP block) decreases systemic morphine requirements after abdominal surgery. We compared intraoperative surgeon-administered TAP block (surgical TAP) to anesthesiologist-administered transcutaneous ultrasound-guided TAP block (conventional TAP) for post-cesarean analgesia. We hypothesized that surgical TAP blocks would take less time to perform than conventional TAP blocks. METHODS: We performed a randomized trial, recruiting 41 women undergoing cesarean delivery under neuraxial anesthesia, assigning them to either surgical TAP block (n=20) or conventional TAP block (n=21). Time taken to perform the block was the primary outcome, while postoperative pain scores and 24-hour opioid requirements were secondary outcomes. Student's t-test was used to compare block time and Kruskal-Wallis test opioid consumption and pain-scores. RESULTS: Time taken to perform the block (2.4 vs 12.1 min, P <0.001), and time spent in the operating room after delivery (55.3 vs 77.9 min, P <0.001) were significantly less for surgical TAP. The 24 h morphine consumption (P=0.17) and postoperative pain scores at 4, 8, 24 and 48 h were not significantly different between the groups. CONCLUSION: Surgical TAP blocks are feasible and less time consuming than conventional TAP blocks, while providing comparable analgesia after cesarean delivery.


Subject(s)
Abdominal Muscles/innervation , Analgesia, Obstetrical/methods , Anesthesiologists , Nerve Block/methods , Pain, Postoperative/prevention & control , Cesarean Section , Humans , Ultrasonography, Interventional
3.
J Perinatol ; 37(12): 1297-1303, 2017 12.
Article in English | MEDLINE | ID: mdl-28981078

ABSTRACT

OBJECTIVE: The fetus is exposed to magnesium administered to the pregnant mother. However, there is controversy regarding magnesium-related neonatal adverse outcomes, largely driven by a limited understanding of the factors that influence neonatal serum magnesium concentrations and associated outcomes. The objective of this study was to examine the relationship between antenatal maternal magnesium dose and serum concentrations, neonatal serum magnesium concentration and immediate neonatal outcomes. STUDY DESIGN: A retrospective study was conducted at a community-based teaching hospital. Neonatal serum magnesium concentrations within 48 h of birth were used to stratify magnesium-exposed neonates into three groups: group 1: <2.5 mg dl-1, group 2: ⩾2.5 to <4.5 mg dl-1, and group 3:⩾4.5 mg dl-1. Immediate neonatal outcomes were compared between the three groups. Total maternal magnesium dose and serum magnesium concentrations before the delivery were correlated with neonatal serum magnesium concentrations and outcomes. RESULTS: Of the 304 mother-baby dyads between 24 and 34 weeks gestation, 237 received antenatal magnesium. Neonatal serum magnesium concentration was 3.14±0.83 mg dl-1 in exposed and 1.96±0.42 mg dl-1 in unexposed neonates (P<0.001). Compared with group 2, neonates had higher odds of grade 3 or 4 intraventricular hemorrhage in group 1 (adjusted odds ratio (AOR) 5.95 (95% confidence interval (CI) 1.05 to 33.66)) and group 3 (AOR 8.42 (95% CI 1.35 to 52.54)). Group 3 neonates also had increased odds of periventricular leukomalacia (AOR: 5.37 (95% CI 1.02 to 28.28) compared with group 2 neonates. Predictors of neonatal serum magnesium concentrations included maternal magnesium dose (r=0.66, P<0.0001), duration of therapy (r=0.70, P<0.0001) and serum concentration (r=0.72, P<0.001). CONCLUSION: The between-group differences highlight that there is a therapeutic range of neonatal serum magnesium concentrations for neuroprotective effects of antenatal magnesium sulfate, while concentrations outside of this range may be associated with adverse neonatal outcomes. Further studies are needed to determine the optimal dose and duration of maternal magnesium to minimize adverse neonatal outcomes.


Subject(s)
Magnesium Sulfate/administration & dosage , Magnesium/blood , Neuroprotective Agents/administration & dosage , Tocolytic Agents/administration & dosage , Adult , Case-Control Studies , Cerebral Intraventricular Hemorrhage/epidemiology , Dose-Response Relationship, Drug , Female , Gestational Age , Humans , Infant, Newborn , Infant, Newborn, Diseases/epidemiology , Infusions, Intravenous , Leukomalacia, Periventricular/epidemiology , Magnesium Sulfate/adverse effects , Male , Neuroprotective Agents/adverse effects , Pregnancy , Retrospective Studies , Tocolytic Agents/adverse effects , Young Adult
4.
J Neonatal Perinatal Med ; 9(4): 333-339, 2016.
Article in English | MEDLINE | ID: mdl-28009336

ABSTRACT

OBJECTIVE: We sought to determine whether hypocortisolism is associated with preterm birth, using hair cortisol as a marker of long term hypothalamic-pituitary-adrenal axis activity. STUDY DESIGN: In a prospective, matched, case-control study, 29 women who had a preterm birth at 24-36w5d gestation were compared to 29 women who delivered at term, matched for maternal age, gestational age, and ethnicity. Cases' samples were collected within 72 h of preterm birth and controls at the same gestational age as the corresponding case. Participants completed validated questionnaires regarding general stress and childhood trauma. The Wilcoxon signed-rank test was used to compare the distribution of mean hair cortisol scores between cases and controls. Conditional logistic regression was used to predict case vs. control by hair cortisol score, controlling for relevant covariates. RESULTS: Baseline characteristics of cases and controls did not differ. Hair cortisol levels were significantly lower among cases in the adjusted analysis. Hair cortisol level was a predictor of case versus control. Each 10-pg.mg-1 increase in hair cortisol level was associated with an estimated 33% decreased odds of being a case. The only significant difference in the validated questionnaires was an increased measure of emotional neglect in the preterm group. CONCLUSION: Our study suggests that women who deliver prematurely may have lower hair cortisol levels than women who deliver at term. Normal hypothalamic-pituitary-adrenal axis activation is a physiologic, adaptive response to stress. One hypothesis to explain our results are that women who are stressed, but unable to mount an adequate stress response could be at particular risk for preterm birth.


Subject(s)
Adult Survivors of Child Adverse Events , Hydrocortisone/metabolism , Premature Birth/metabolism , Stress, Psychological/metabolism , Adult , Adult Survivors of Child Adverse Events/psychology , Case-Control Studies , Female , Gestational Age , Hair/chemistry , Humans , Hypothalamo-Hypophyseal System , Logistic Models , Maternal Age , Odds Ratio , Pilot Projects , Pituitary-Adrenal System , Pregnancy , Premature Birth/epidemiology , Premature Birth/psychology , Prospective Studies , Stress, Psychological/epidemiology , Stress, Psychological/psychology , Surveys and Questionnaires
5.
J Frailty Aging ; 5(1): 43-8, 2016.
Article in English | MEDLINE | ID: mdl-26980368

ABSTRACT

BACKGROUND: Biological similarities are noted between aging and HIV infection. Middle-aged adults with HIV infection may present as elderly due to accelerated aging or having more severe aging phenotypes occurring at younger ages. OBJECTIVES: We explored age-adjusted prevalence of frailty, a geriatric condition, among HIV+ and at risk HIV- women. DESIGN: Cross-sectional. SETTING: The Women's Interagency HIV Study (WIHS). PARTICIPANTS: 2028 middle-aged (average age 39 years) female participants (1449 HIV+; 579 HIV-). MEASUREMENTS: The Fried Frailty Index (FFI), HIV status variables, and constellations of variables representing Demographic/health behaviors and Aging-related chronic diseases. Associations between the FFI and other variables were estimated, followed by stepwise regression models. RESULTS: Overall frailty prevalence was 15.2% (HIV+, 17%; HIV-, 10%). A multivariable model suggested that HIV infection with CD4 count<200; age>40 years; current or former smoking; income ≤$12,000; moderate vs low fibrinogen-4 (FIB-4) levels; and moderate vs high estimated glomerular filtration rate (eGFR) were positively associated with frailty. Low or moderate drinking was protective. CONCLUSIONS: Frailty is a multidimensional aging phenotype observed in mid-life among women with HIV infection. Prevalence of frailty in this sample of HIV-infected women exceeds that for usual elderly populations. This highlights the need for geriatricians and gerontologists to interact with younger 'at risk' populations, and assists in the formulation of best recommendations for frailty interventions to prevent early aging, excess morbidities and early death.


Subject(s)
Aging/physiology , Frail Elderly/statistics & numerical data , HIV Infections , Adult , Aged , CD4 Lymphocyte Count/methods , Female , Fibrinogen/analysis , HIV Infections/blood , HIV Infections/diagnosis , HIV Infections/epidemiology , Health Status Disparities , Health Status Indicators , Humans , Middle Aged , Risk Assessment/methods , Risk Factors , Smoking/epidemiology , Socioeconomic Factors , Statistics as Topic
6.
J Viral Hepat ; 22(12): 1055-60, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26115445

ABSTRACT

African Americans coinfected with HIV and hepatitis C virus (HCV) have lower liver-related mortality than Caucasians and Hispanics. While genetic polymorphisms near the IFNL3 and IFNL4 genes explain a significant fraction of racial differences in several HCV-related outcomes, the impact of these variants on liver-related mortality has not been investigated. We conducted a cohort study of HIV/HCV-coinfected women followed in the multicentre, NIH-funded Women's Interagency HIV Study (WIHS) to investigate whether 10 polymorphisms spanning the IFN-λ region were associated with liver-related mortality by dominant, recessive or additive genetic models. We also considered whether these polymorphisms contributed to previously reported differences in liver-related death by race/ethnicity (ascertained by self-report and ancestry informative markers). Among 794 coinfected women, there were 471 deaths including 55 liver-related deaths during up to 18 years of follow-up. On adjusted analysis, rs12980275 GG genotype compared to AG+AA hazards ratios [(HR) 0.36, 95% CI 0.14-0.90, P = 0.029] and rs8109886 AA genotype compared to CC+AC (HR 0.67, 95% CI 0.45-0.99, P = 0.047) were most strongly associated with liver-related death although these associations were no longer significant after adjusting for race/ethnicity (HR 0.41, 95% CI 0.16-1.04, P = 0.060 and HR 0.78, 95% CI 0.51-1.19, P = 0.25, respectively). African American women had persistently lower liver-related death independent of IFN-λ variants (HRs ≤ 0.44, P values ≤ 0.04). The lower risk of death among African American HIV/HCV-coinfected women is not explained by genetic variation in the IFN-λ region suggesting, that other genetic, behavioural and/or environmental factors may contribute to racial/ethnic differences in liver-related mortality.


Subject(s)
Black or African American/genetics , HIV Infections/mortality , Hepatitis C, Chronic/mortality , Interleukins/genetics , Cohort Studies , Coinfection/virology , Female , Genetic Predisposition to Disease , Genotype , HIV Infections/complications , HIV Infections/virology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/virology , Humans , Interferons , Liver/pathology , Polymorphism, Single Nucleotide/genetics , Prospective Studies
7.
HIV Med ; 14(9): 549-55, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23738819

ABSTRACT

OBJECTIVES: HIV infection is associated with higher than expected cardiovascular event rates and lowered platelet counts. These conditions are associated with an elevation of mean platelet volume (MPV). The present study compared MPV in HIV-infected and uninfected women and identified factors influencing MPV values in HIV-infected women. METHODS: A total of 234 HIV-infected and 134 HIV-uninfected participants from the Women's Interagency HIV Study (WIHS) had MPV values obtained. HIV-infected women were older, were more likely to have diabetes and had higher triglyceride levels than HIV-uninfected women. RESULTS: The mean platelet count was lower in HIV-infected vs. uninfected women [249 cells/µL (95% confidence interval (CI) 238, 259 cells/µL) vs. 276 cells/µL (95% CI 265, 287 cells/µL), respectively; P < 0.01]. Adjusted mean MPV values were lower in the HIV-infected than in the uninfected group [8.66 fL (95% CI 8.52, 8.79 fL) vs. 9.05 fL (95% CI 8.87, 9.24 fL), respectively]. In multiple regression analysis, after adjusting for other covariates, MPV was positively associated with platelet count, and negatively with HIV infection (model R² = 0.20; P < 0.01). In multiple regression analysis confined to HIV-infected women, a lower MPV was independently associated with a history of AIDS-defining illness (R² = 0.28; P = 0.03), but not with nadir CD4 count or highly active antiretroviral therapy (HAART) use. CONCLUSIONS: HIV-infected women had lower MPV values than uninfected women, suggesting impaired production rather than increased destruction. Higher than expected cardiovascular event rates cannot be attributed to greater platelet reactivity as measured by MPV.


Subject(s)
HIV Infections/blood , Mean Platelet Volume , Adult , Antiretroviral Therapy, Highly Active/adverse effects , Case-Control Studies , Cross-Sectional Studies , Female , HIV Infections/complications , HIV Infections/drug therapy , Humans , Middle Aged , Risk Factors , United States/epidemiology
8.
Genes Immun ; 14(5): 330-5, 2013.
Article in English | MEDLINE | ID: mdl-23636221

ABSTRACT

Human leukocyte antigen (HLA) genotype has been associated with the probability of spontaneous clearance of hepatitis C virus (HCV). However, no prior studies have examined whether this relationship may be further characterized by grouping HLA alleles according to their supertypes, defined by their binding capacities. There is debate regarding the most appropriate method to define supertypes. Therefore, previously reported HLA supertypes (46 class I and 25 class II) were assessed for their relation with HCV clearance in a population of 758 HCV-seropositive women. Two HLA class II supertypes were significant in multivariable models that included: (i) supertypes with significant or borderline associations with HCV clearance after adjustment for multiple tests, and (ii) individual HLA alleles not part of these supertypes, but associated with HCV clearance in our prior study in this population. Specifically, supertype DRB3 (prevalence ratio (PR)=0.4; P=0.004) was associated with HCV persistence, whereas DR8 (PR=1.8; P=0.01) was associated with HCV clearance. Two individual alleles (B*57:01 and C*01:02) associated with HCV clearance in our prior study became nonsignificant in analysis that included supertypes, whereas B*57:03 (PR=1.9; P=0.008) and DRB1*07:01 (PR=1.7; P=0.005) retained their significance. These data provide epidemiologic support for the significance of HLA supertypes in relation to HCV clearance.


Subject(s)
HLA Antigens/immunology , HLA-B Antigens/immunology , HLA-DR Serological Subtypes/immunology , HLA-DRB1 Chains/immunology , Hepacivirus/immunology , Hepatitis C/immunology , Female , HLA Antigens/classification , HLA Antigens/genetics , HLA-B Antigens/genetics , HLA-DR Serological Subtypes/genetics , HLA-DRB1 Chains/genetics , Hepatitis C/genetics , Hepatitis C/virology , Humans , Multivariate Analysis , Review Literature as Topic
9.
Int J STD AIDS ; 22(5): 273-7, 2011 May.
Article in English | MEDLINE | ID: mdl-21571975

ABSTRACT

We identified demographic, clinical and biological determinants of herpes simplex virus type 2 (HSV-2) shedding among HIV-infected participants in the Women's HIV Interagency Study (WIHS). Cervicovaginal lavage (CVL) specimens from 369 HIV-infected HSV seropositive women were tested with TaqMan polymerase chain reaction (PRC) for detection HSV-2 DNA. Seven percent of women tested positive for HSV-2 DNA in CVL. Significant correlates of the presence of HSV-2 DNA in CVL were being younger, African American or Hispanic race/ethnicity and injecting drugs in the past six months (P < 0.05). A borderline significant trend for reduced viral shedding with higher CD4+ T cell counts was observed (P = 0.08). All women who were never observed with any genital lesions and had consistently negative self-reported history of genital sores throughout the follow-up (n = 29, 8%) were negative for CVL HSV-2 DNA. HSV-2 DNA quantity was significantly associated with having frequent subsequent lesion recurrences (Spearman rho = 0.48, P = 0.016; adjusted prevalence ratio [APR] = 2.5, P = 0.012). Increasing the age of the host was inversely correlated with decreased viral shedding over time. However, a subset of older women continued to shed significant amounts of virus despite passage of time. This study provides genital HSV-2 DNA titre as a quantitative and symptom- and sign-based measures as qualitative predictors of HSV-2 shedding from the lower genital tract among HIV-infected women.


Subject(s)
HIV Infections/complications , Herpes Genitalis/diagnosis , Herpes Genitalis/virology , Herpesvirus 2, Human/isolation & purification , Virus Shedding , Adult , Antibodies, Viral/blood , DNA, Viral/blood , Female , Herpes Genitalis/pathology , Herpesvirus 2, Human/genetics , Humans , Polymerase Chain Reaction , Risk Factors , Vaginal Douching
11.
HIV Med ; 8(8): 555-60, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17944689

ABSTRACT

OBJECTIVE: Although HIV infection has been associated with increased risk of subclinical atherosclerosis and cardiovascular events, peripheral arterial disease (PAD) has not been assessed in HIV-infected patients. The objective of this study was to determine the prevalence of, and risk factors for, PAD using ankle-brachial index (ABI) measurement in HIV-infected and uninfected women. METHODS: ABI was determined for 335 participants in the Women's Interagency HIV Study (WIHS). A cross-sectional analysis was conducted to determine factors associated with high (>or=1.40) ABI. RESULTS: The prevalence of low ABI (or=1.40) was 6.9% (n=23). The prevalence of low ABI was too low to allow risk factor analysis. On multivariate analysis, factors associated with high ABI were current cigarette smoking [adjusted odds ratio (OR(adj)) 2.53, 95% confidence interval (CI) 0.99-6.43], being underweight (OR(adj) 11.0, 95% CI 1.61-75.63) and being overweight (OR(adj) 5.40, 95% CI 1.13-25.89). CONCLUSIONS: Although the prevalence of ABI or=1.40 was unexpectedly high. Further studies are indicated to determine the clinical significance of high ABI and its relation to the risk of cardiovascular events in HIV-infected women.


Subject(s)
Cardiovascular Diseases/prevention & control , HIV Infections/complications , Peripheral Vascular Diseases/etiology , Adult , Ankle , Blood Pressure , Brachial Artery/diagnostic imaging , Cross-Sectional Studies , Female , Humans , Odds Ratio , Peripheral Vascular Diseases/diagnostic imaging , Risk Assessment , Risk Factors , Ultrasonography
12.
Pharmacogenomics J ; 6(4): 255-64, 2006.
Article in English | MEDLINE | ID: mdl-16477274

ABSTRACT

Fetal development is a period sensitive to environmental influences such as maternal drug use. The most commonly used illicit drug by pregnant women is marijuana. The present study investigated the effects of in utero marijuana exposure on expression levels of opioid-related genes in the human fetal forebrain in light of the strong interaction between the cannabinoid and opioid systems. The study group consisted of 42 midgestation fetuses from saline-induced voluntary abortions. The opioid peptide precursors (preprodynorphin and preproenkephalin (PENK)) and receptor (mu, kappa and delta) mRNA expression were assessed in distinct brain regions. The effect of prenatal cannabis exposure was analyzed by multiple regression controlling for confounding variables (maternal alcohol and cigarette use, fetal age, sex, growth measure and post-mortem interval). Prenatal cannabis exposure was significantly associated with increased mu receptor expression in the amygdala, reduced kappa receptor mRNA in mediodorsal thalamic nucleus and reduced preproenkephalin expression in the caudal putamen. Prenatal alcohol exposure primarily influenced the kappa receptor mRNA with reduced levels in the amygdala, claustrum, putamen and insula cortex. No significant effect of prenatal nicotine exposure could be discerned in the present study group. These results indicate that maternal cannabis and alcohol exposure during pregnancy differentially impair opioid-related genes in distinct brain circuits that may have long-term effects on cognitive and emotional behaviors.


Subject(s)
Dynorphins/genetics , Enkephalins/genetics , Fetus/drug effects , Gene Expression Regulation, Developmental , Marijuana Smoking/adverse effects , Prosencephalon/drug effects , Protein Precursors/genetics , Receptors, Opioid/genetics , Adult , Alcohol Drinking/adverse effects , Dynorphins/metabolism , Enkephalins/metabolism , Female , Gestational Age , Humans , In Situ Hybridization , Pregnancy , Prenatal Exposure Delayed Effects , Prosencephalon/embryology , Protein Precursors/metabolism , RNA, Messenger/metabolism , Receptors, Opioid/metabolism
13.
Neurotoxicol Teratol ; 27(2): 221-9, 2005.
Article in English | MEDLINE | ID: mdl-15734273

ABSTRACT

Marijuana (Cannabis sativa) is the most commonly used illicit drug by pregnant women, but information is limited about the effects of prenatal cannabis exposure on fetal development. The present study evaluated the influence of early maternal marijuana use on fetal growth. Women electing voluntary saline-induced abortions were recruited at a mid-gestational stage of pregnancy (weeks 17-22), and detailed drug use and medical histories were obtained. Toxicological assays (maternal urine and fetal meconium) were used in conjunction with the maternal report to assign groups. Subjects with documented cocaine and opiate use were excluded. Main developmental outcome variables were fetal weight, foot length, body length, and head circumference; ponderal index was also examined. Analyses were adjusted for maternal alcohol and cigarette use. Marijuana (n=44)- and nonmarijuana (n=95)-exposed fetuses had similar rates of growth with increased age. However, there was a 0.08-cm (95% CI -0.15 to -0.01) and 14.53-g (95% CI -28.21 to 0.86) significant reduction of foot length and body weight, respectively, for marijuana-exposed fetuses. Moreover, fetal foot length development was negatively correlated with the amount and frequency of marijuana use reported by the mothers. These findings provide evidence of a negative impact of prenatal marijuana exposure on the mid-gestational fetal growth even when adjusting for maternal use of other substances well known to impair fetal development.


Subject(s)
Cannabis/toxicity , Fetal Development/drug effects , Marijuana Smoking/physiopathology , Prenatal Exposure Delayed Effects , Adult , Birth Weight/drug effects , Body Height/drug effects , Confidence Intervals , Female , Fetal Weight/drug effects , Fetus , Humans , Immunoassay/methods , Infant, Newborn , Marijuana Smoking/urine , Meconium/drug effects , Pregnancy
14.
Sex Transm Infect ; 78(3): 208-9, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12238656

ABSTRACT

OBJECTIVES: Ligase chain reaction (LCR) technology has dramatically increased the sensitivity of tests for sexually transmitted infections (STIs). It is unknown whether low copy infections (LCR positive, culture negative) have any clinical consequences. We assessed the clinical significance of untreated low copy Chlamydia trachomatis and Neisseria gonorrhoeae infections in a cohort of sexually active women. METHODS: We studied a cohort of sexually active women followed at 6 month intervals for up to 3 years. Frozen urine specimens from 181 women with negative cultures for C. trachomatis and N. gonorrhoeae who were 'high risk' (defined as being less than 40 years old at baseline, and having either Trichomonas vaginalis at baseline or a history of more than one sexual partner during the 12 months before baseline) were tested for C. trachomatis and N. gonorrhoeae by LCR (Abbott Laboratories, Abbott Park, IL, USA). The specimens from all visits for each person were pooled and LCR was performed on the pool. Laboratory results were linked to clinical information. We also tested all urine samples obtained from patients with a positive culture. RESULTS: 10 additional infections (nine C. trachomatis and one N. gonorrhoeae) were detected with LCR technique. None of the women with low copy infection had evidence of subsequent pelvic inflammatory disease or ectopic pregnancy. Pooling of urine samples resulted in a 47% decline in the number of tests performed. CONCLUSIONS: Additional STIs can be identified when using LCR. Pooling of urine specimens is a cost saving technique for C. trachomatis and N. gonorrhoeae testing.


Subject(s)
Chlamydia Infections/epidemiology , Gonorrhea/epidemiology , Ligase Chain Reaction/methods , Uterine Cervical Diseases/epidemiology , Adult , Chlamydia Infections/diagnosis , Chlamydia trachomatis/isolation & purification , Cohort Studies , Female , Follow-Up Studies , Gonorrhea/diagnosis , Humans , Middle Aged , Neisseria gonorrhoeae/isolation & purification , New York City/epidemiology , Pelvic Inflammatory Disease/epidemiology , Pelvic Inflammatory Disease/microbiology , Risk Factors , Uterine Cervical Diseases/microbiology
15.
J Epidemiol Community Health ; 56(2): 153-9, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11812817

ABSTRACT

STUDY OBJECTIVE: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. DESIGN: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. SETTING: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). PARTICIPANTS: A total of 1691 HIV seropositive women with a study visit after April 1996. MAIN RESULTS: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. CONCLUSIONS: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , Adolescent , Adult , Aged , CD4-CD8 Ratio , CD4-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/drug effects , Cohort Studies , Female , HIV Infections/mortality , Humans , Middle Aged , United States/epidemiology
16.
Lancet ; 358(9293): 1593-601, 2001 Nov 10.
Article in English | MEDLINE | ID: mdl-11716886

ABSTRACT

BACKGROUND: Plasma HIV-1 RNA concentration has been the best predictor for risk of heterosexual and perinatal transmission. However, direct contact with HIV-1 present locally in the genital tract might be necessary for transmission. We aimed to assess the relation between HIV-1 shedding (RNA or culturable virus) in female genital secretions and other factors that might affect HIV-1 shedding. METHODS: This was a cross-sectional study within the Women's Interagency HIV Study (WIHS), a prospective longitudinal cohort study of HIV-infected women. We enrolled 311 HIV positive women from Jan 30, 1997 to July 1, 1998. We did clinical assessments, cultured HIV-1, and measured RNA in peripheral blood mononuclear cells (PBMC) and genital secretions. We compared the results with univariate and multivariate analyses. Presence of HIV-1 RNA or culturable virus in genital secretions was defined as HIV-1 shedding. FINDINGS: HIV-1 RNA was present in genital secretions of 57% (152/268) of women whereas infectious virus was detected only in 6% (17/271). Genital tract HIV-1 shedding was found in 80% (130/163) of women with detectable plasma RNA and 78% (116/148) of women with positive PBMC cultures. 33% (27/83) of women with less than 500 copies/mL plasma RNA and 39% (35/90) of those with negative PBMC cultures also had genital tract shedding. INTERPRETATION: Plasma RNA concentration, both qualitatively and quantitatively, was the most important factor in predicting genital HIV-1 shedding, even among women receiving potent antiretroviral therapy. However, HIV-1 shedding did occur in women with less than 500 copies/mL plasma HIV-1 RNA. This finding suggests that a separate reservoir of HIV-1 replication may exist in some women.


Subject(s)
Genitalia, Female/virology , HIV-1/isolation & purification , Virus Shedding , Adult , Cross-Sectional Studies , Female , Humans , Middle Aged , Multicenter Studies as Topic , Prospective Studies , RNA, Viral/blood , Risk Factors , United States/epidemiology , Virus Diseases/diagnosis , Virus Diseases/epidemiology
17.
Am J Public Health ; 91(11): 1857-64, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11684616

ABSTRACT

OBJECTIVES: This study analyzed changes in the financing of prenatal care and delivery, the use of prenatal care, and birth outcomes among foreign-born vs US-born Latino women following enactment of the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA) in August 1996. METHODS: We used a pre-post design with a comparison group. The sample consisted of resident Latinas in California, New York City, and Texas who delivered a live infant in 1995 or 1998. RESULTS: The proportion of births to Latinas that initiated prenatal care in the first 4 months of pregnancy increased for all foreign-born Latinas in California, New York City, and Texas between 1995 and 1998 (P <.05). Except for non-Dominicans in New York City, there was no increase in the proportion of low- or very-low-birthweight births among foreign-born vs US-born Latinas in the 3 localities between 1995 and 1996. CONCLUSIONS: There is little evidence from vital statistics in California, New York City, and Texas that PRWORA had any substantive impact on the perinatal health and health care utilization of foreign-born relative to US-born Latinas.


Subject(s)
Hispanic or Latino/statistics & numerical data , Maternal Welfare/economics , Medicaid/legislation & jurisprudence , Pregnancy Outcome/ethnology , Prenatal Care/statistics & numerical data , California/epidemiology , Eligibility Determination/legislation & jurisprudence , Emigration and Immigration/legislation & jurisprudence , Female , Humans , Maternal Welfare/ethnology , Maternal Welfare/legislation & jurisprudence , Medically Uninsured , Multivariate Analysis , New York City/epidemiology , Pregnancy , Pregnancy Outcome/economics , Prenatal Care/economics , Public Assistance/legislation & jurisprudence , State Health Plans/economics , Texas/epidemiology , United States/epidemiology
18.
AIDS ; 15(16): 2101-8, 2001 Nov 09.
Article in English | MEDLINE | ID: mdl-11684929

ABSTRACT

OBJECTIVE: To characterize predictors and consequences of discontinuing antiretroviral therapy (ART) in terms of CD4 cell count, HIV RNA, and reported side-effects in a large cohort of HIV-infected women. DESIGN: Cohort study. METHODS: A total of 1058 HIV-infected women initiated potent ART before September 1999. For each 6 month period after October 1996 we determined the proportion of potent ART users who downshifted to non-potent ART and who discontinued all ART. We examined the role of CD4 cell count and HIV RNA with regard to ART discontinuation. RESULTS: Between October 1996 and September 1999, 1058 individuals contributed 3362 visits at which potent ART was reported in the previous 6 months. Overall rates of 6 month downshifting and discontinuation were 10.0% and 6.7%. The proportion of individuals discontinuing all ART increased from 2.9% in late 1996 to 9.1% in mid 1999 (P < 0.001). Individuals with high HIV RNA levels were more likely to discontinue (P < 0.05). Compared to those who continued on potent ART, individuals who discontinued experienced large declines (P < 0.001) in CD4 cell counts and were more than three times more likely (P < 0.001) to experience HIV RNA increases. However, over one-third of those discontinuing ART reported side-effects and this subset had smaller CD4 cell count declines as compared to discontinuers not reporting side-effects (P = 0.147). CONCLUSIONS: In a large cohort of HIV-infected women, an increasing proportion of potent ART users discontinued ART over 3 years. Higher HIV RNA levels predicted discontinuation. Immediate immunological/virological deleterious consequences were observed. Side-effects were the most common reason for discontinuation and CD4 cell count declines were larger among those who did not cite side-effects as the reason for discontinuation.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , HIV Infections/immunology , HIV-1/physiology , Reverse Transcriptase Inhibitors/administration & dosage , Adult , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Cohort Studies , Drug Administration Schedule , Drug Therapy, Combination , Female , HIV Infections/virology , Humans , Predictive Value of Tests , RNA, Viral/blood , Reverse Transcriptase Inhibitors/therapeutic use , Treatment Outcome
19.
AIDS ; 15(16): 2157-64, 2001 Nov 09.
Article in English | MEDLINE | ID: mdl-11684935

ABSTRACT

OBJECTIVE: Cervical intraepithelial neoplasia (CIN), a common condition among HIV-infected women, has been linked to HIV load and immune status. Highly active antiretroviral therapy (HAART) improves immunologic and virologic status. This study was undertaken to determine the relationship between HAART use and CIN. DESIGN: Cohort study. The Women's Interagency HIV Study (WIHS) in five cities in the USA (Bronx/Manhattan, New York; Brooklyn, New York; Chicago, Illinois; Los Angeles, California; San Francisco Bay area, California; Washington, District of Columbia). METHODS: HIV-infected women were followed every 6 months with Papanicolaou smears and cervicovaginal lavage for human papillomavirus (HPV) DNA testing. To characterize exposures that changed over time and to capture the dynamic nature of cytologic changes, Papanicolaou smear findings from each participant's consecutive visits were defined as a pair. We determined the proportion of all pairs that exhibited either regression or progression, according to HAART exposure, HPV results and Papanicolaou smear status. As participants could contribute multiple pairs, inferences were based on robust methods to adjust for correlated observations. RESULTS: Women with persistent HPV infection were more likely to have progression of their lesions. After adjustment for CD4 cell count and Papanicolaou smear status, women on HAART were 40% (95% confidence interval, 4-81%) more likely to demonstrate regression and less likely (odds ratio, 0.68; 95% confidence interval, 0.52-0.88) to demonstrate progression CONCLUSIONS: HAART altered the course of HPV disease in HIV-infected women, reducing progression and increasing regression. As HPV disease is a common sex-specific manifestation of HIV disease this effect of HAART would be a major additional benefit from this modality of therapy.


Subject(s)
Antiretroviral Therapy, Highly Active , Cervix Uteri/pathology , HIV Infections/complications , Papillomavirus Infections/drug therapy , Tumor Virus Infections/drug therapy , Uterine Cervical Dysplasia/drug therapy , Adolescent , CD4 Lymphocyte Count , Cervix Uteri/cytology , Cervix Uteri/virology , Cohort Studies , DNA, Viral/analysis , Female , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/physiology , Humans , Papanicolaou Test , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Treatment Outcome , Tumor Virus Infections/complications , Tumor Virus Infections/pathology , Tumor Virus Infections/virology , Vaginal Smears , Uterine Cervical Dysplasia/complications , Uterine Cervical Dysplasia/pathology
20.
J Acquir Immune Defic Syndr ; 27(5): 432-42, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11511819

ABSTRACT

OBJECTIVE: To determine incidence, progression, and regression rates for abnormal cervical cytology and their correlates among women with HIV. METHODS: In a multicenter prospective cohort study conducted October 1, 1994, through September 30, 1999 at university, public, and private medical centers and clinics, 1639 HIV-seropositive and 452 seronegative women were evaluated every 6 months for up to 5 years using history, cervical cytology, T-cell subsets, and quantitative plasma HIV RNA. Human papillomavirus (HPV) typing at baseline was determined by polymerase chain reaction. Cytology was read using the Bethesda system, with any smear showing at least atypia considered abnormal. Poisson regression identified factors associated with incident cytologic abnormalities whereas logistic regression identified those associated with progression and regression after an abnormality. RESULTS: At least one abnormal smear was found during all of follow-up among 73.0% of HIV-seropositive patients and 42.3% of seronegatives (p <.001). Only 5.9% of seropositives ever developed high-grade lesions, and the proportion with high-grade findings did not rise over time. Incidence of atypical squamous cells of uncertain significance (ASCUS) or more severe lesions among HIV-seropositive patients and seronegative patients was 26.4 and 11.0/100 woman-years (rate ratio [RR], 2.4; 95% confidence interval [CI], 1.9-3.0), whereas that of at least low-grade squamous intraepithelial lesions (SIL) was 8.9 and 2.2/100 (RR, 4.0; CI, 2.6-6.1). HIV status, detection of the presence of human papillomavirus (HPV), CD4 lymphocyte count, and HIV RNA level predicted incidence of abnormal cytology (p <.05); HPV detection and HIV RNA level predicted progression (p <.01); and HPV detection, CD4 lymphocyte count, and HIV RNA level predicted regression (p <.001). Rates of incidence, progression, and regression of abnormal cytology did not differ between HIV seronegative women and seropositive women with CD4 lymphocyte counts >200/mm(3) and HIV RNA levels <4000/ml of similar HPV status. CONCLUSIONS: Although HIV infected women were at high risk for abnormal cytology, high-grade changes were uncommon. HIV status, HPV detection, CD4 lymphocyte count, and HIV RNA level predicted the incidence of cervical cytologic abnormalities. Progression was significantly increased only among the most immunosuppressed women, while regression was significantly reduced in all HIV seropositive women except those with the best controlled HIV disease.


Subject(s)
HIV Infections/complications , Papillomavirus Infections/epidemiology , Tumor Virus Infections/epidemiology , Uterine Cervical Diseases/epidemiology , Uterine Cervical Dysplasia/epidemiology , Vaginal Smears , Adult , CD4 Lymphocyte Count , Cohort Studies , Disease Progression , Female , HIV-1/isolation & purification , Humans , Incidence , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Papillomavirus Infections/diagnosis , Population Surveillance , Prognosis , Prospective Studies , RNA, Viral/blood , Risk Factors , Tumor Virus Infections/complications , Tumor Virus Infections/diagnosis , Uterine Cervical Diseases/diagnosis , Uterine Cervical Dysplasia/complications , Uterine Cervical Dysplasia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...